Literature DB >> 21492223

Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation.

Kasper Drimer Berg1, Birgitte Grønkaer Toft, Martin Andreas Røder, Klaus Brasso, Ben Vainer, Peter Iversen.   

Abstract

Histopathological grading of prostate cancer (PCa) is associated with significant interobserver variability. This, as well as clinical consequences of histopathological re-evaluation, was investigated. In 350 patients, histopathological re-evaluations of prostate biopsies were compared with primary pathology reports and with histopathology of the radical prostatectomy specimen. The consequences of re-evaluation for clinical workup and treatment of patients according to local algorithms were determined. For Gleason score (GS), complete agreement between primary report and re-evaluation was found in 76.9%. The cancers were assessed with higher GS at re-evaluation in 25.0% of patients in cases with primary GS ≤ 6, while scores were devaluated in 3.0% and 10.3% of the patients with primary GS = 7 and ≥ 8, respectively. Strategies for clinical evaluation and treatment were changed as a result of the biopsy re-evaluations in 19.7% and 13.1% of patients, respectively. Gleason scoring based on the radical prostatectomy specimen was higher than in both primary reports and re-evaluation of biopsies. Although a relatively high degree of concordance was found between biopsy assessments, the significant trend towards higher Gleason scoring at re-evaluation, leading to frequent changes in clinical assessments and surgical strategy, justifies re-evaluation of PCa biopsies in patients with primary GS ≤ 6.
© 2011 The Authors. APMIS © 2011 APMIS.

Entities:  

Mesh:

Year:  2011        PMID: 21492223     DOI: 10.1111/j.1600-0463.2011.02723.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

1.  The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.

Authors:  Christian Arsov; Nikolaus Becker; Robert Rabenalt; Andreas Hiester; Michael Quentin; Frederic Dietzel; Gerald Antoch; Helmut E Gabbert; Peter Albers; Lars Schimmöller
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-27       Impact factor: 4.553

2.  High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance.

Authors:  Isabel Heidegger; Viktor Skradski; Eberhard Steiner; Helmut Klocker; Renate Pichler; Andreas Pircher; Wolfgang Horninger; Jasmin Bektic
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

3.  Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?

Authors:  Ning Xu; Yu-Peng Wu; Xiao-Dong Li; Min-Yi Lin; Qing-Shui Zheng; Shao-Hao Chen; Jun-Feng Li; Yong Wei; Xue-Yi Xue
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

4.  The importance of histopathologic review of biopsies in patients with prostate cancer referred to a tertiary uro-oncology center.

Authors:  Wagner Eduardo Matheus; Ubirajara Ferreira; Elimilson A Brandão; Aline A Ferruccio; Athanase Billis
Journal:  Int Braz J Urol       Date:  2019 Jan-Feb       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.